

**21-22 JUNE 2025**

DUSIT THANI ABU DHABI, UAE

## CONFERENCE PROGRAM

**DAY 1**



**21 June 2025** (Saturday)



**09:00 - 17:30**

08:45 – 09:00

Introduction

**Dr. Jawaher Ansari, UAE** (Conference Chair)

**Dr. Khalid Balaraj, UAE** (Conference Co-chair)

### SESSION 1: METASTATIC BREAST CANCER

Moderators: Dr. Maroun El Khoury, UAE | Dr. Dorai Ramanathan, UAE | Dr. Soni Soumian, UAE

09:00 – 09:10

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs THP for first-line (1L) treatment of pts with HER2+ advanced/metastatic breast cancer: DESTINY-Breast09.

**Prof. Gregory Vidal, USA**

09:10 – 09:20

Sacituzumab govitecan (SG) + pembro vs chemo + pembro in previously untreated PD-L1 positive advanced TNBC: ASCENT-04/KEYNOTE-D19 study.

**Dr. Husam Marashi, UAE**

09:20 – 09:30

Vepdegestrant vs fulvestrant in ER-positive/HER2-negative advanced breast cancer: VERITAC-2 study.

**Prof. Debu Tripathy, USA**

09:30 – 09:40

INAVO120: Phase III trial final OS analysis of first-line inavolisib/placebo (PBO) + PALBO + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, HR+, HER2-negative (HER2-), endocrine-resistant advanced breast cancer.

**Dr. Saeed Rafii, UAE**

09:40 – 09:50

Camizestrant + CDK4/6 i for the treatment of emergent ESR1 mutations during 1L ET and ahead of PD in pts with HR+/HER2- advanced breast cancer: SERENA-6 trial.

**Dr. Jawaher Ansari, UAE**

09:50 – 10:00

Randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and ER+ breast cancer following progression on first line CDK 4/6i and AI: The CCTG/BCT MA.40/FINER study.

**Dr. Anwar Alnouri, Kuwait**

10:00 – 10:20

Panel discussion and Q&A

Discussant and Moderator: **Dr. Maroun El Khoury, UAE**

Panel: **All Speakers**

10:20 – 10:35

Transforming Patient Care: Evidence-Based Medicine in HR+ HER-2 mBC - **Supported by Novartis**

**Dr. Dina Hamza, UAE**

\*Subject to changes

OPENING CEREMONY	
10:35 - 10:40	Introduction & National Anthem
10:40 - 10:45	Promotional Videos - SEHA Tawam Hospital
10:45 - 11:00	Cross-Cutting Themes from ASCO 2025: Driving Knowledge to Action <b>Prof. Julie Gralow, USA</b> Executive Vice President and Chief Medical Officer, American Society of Clinical Oncology (ASCO)
11:00 - 11:15	Opening Speech <b>Dr. Jawaher Ansari, UAE</b> Conference Chair and Chief of Medical Oncology, SEHA Tawam Hospital
11:15 - 11:30	<b>Coffee Break</b>
SESSION 2: EARLY BREAST CANCER	
Moderators: Dr. Mouza Al Ameri, UAE   Dr. Aly Abdel Razek, UAE   Dr. Aladdin Marraoui, UAE	
11:30 - 11:40	De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2+ EBC: neoCARHP Trial <b>Dr. Faisal Alterkait, Kuwait</b>
11:40 - 11:50	Predicting pCR from clinicopathologic variables and HER2DX in stage II/III HER2+ breast cancer treated with THP: EA1181/CompassHER2 pCR trial. <b>Prof. Khalid Alsaleh, KSA</b>
11:50 - 12:00	15-year outcomes for women with premenopausal HR+ EBC in the SOFT and TEXT trials assessing benefits from adjuvant exemestane + OFS or tamoxifen +OFS. <b>Dr. Nouri Bennini, UAE</b>
12:00 - 12:10	NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative <b>Dr. Bassel Jallad, UAE</b>
12:10 - 12:20	Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial. <b>Dr. Sharif Kullab, KSA</b>
12:20 - 12:40	Panel discussion and Q&A Discussant and Moderator: <b>Dr. Aladdin Marraoui, UAE</b> International Expert: <b>Prof. Julie Gralow, USA</b> Panellists: <b>All Speakers</b>
12:40 - 12:55	Kisqali Breaking New Grounds in HR+ HER- eBC - <b>Supported by Novartis</b> <b>Prof. Debu Tripathy, USA</b>
12:55 - 13:10	From Data to Decisions: Case Discussions around HR+ HER-2 High Risk Breast Cancer Patients - <b>Supported by Lilly</b> Moderator: <b>Dr. Shaheenah Dawood, UAE</b> Panel: <b>Dr. Anwar Alnouri, Kuwait   Dr. Bassel Jallad, UAE   Dr. Jawaher Ansari, UAE</b>
13:10 - 14:30	<b>Lunch Break</b>

\*Subject to changes

### SESSION 3: GU CANCERS

Moderators: Dr. Aftab Ahmad Bhatti, UAE | Dr. Rana Mahmood, UAE | Dr. Nouri Bennini, UAE

14:30 - 14:40	NIVO+IPI vs gem-carbo for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial. <b>Dr. Abdullah Ali Al-Sharm, KSA</b>
14:40 - 14:50	Sasanlimab in combination with BCG in BCG-naïve, high-risk NMIBC: EFS subgroup analyses from the CREST study <b>Dr. Sulaiman Al Saadi, Oman</b>
14:50 - 15:00	NIVO+IPI vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial. <b>Dr. Sai Jonnada, UAE</b>
15:00 - 15:10	Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial. <b>Dr. Syed Tirmazy, UAE</b>
15:10 - 15:20	ARCHES: 5-year follow-up OS analysis of ENZA plus ADT in pts with mHSPC <b>Dr. Deborah Mukherji, UAE</b>
15:20 - 15:30	Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for mCSPC patients with alterations in HRR genes. <b>Dr. Mohammed Ashour, Kuwait</b>
15:30 - 15:50	Panel discussion and Q&A Discussant and Moderator: <b>Dr. Nouri Bennini, UAE</b> Panel: <b>All Speakers</b>
15:50 - 16:05	Practice Changing Data for Lu-PSmA in Chemo Naïve mCRPC - <b>Supported by Novartis</b> <b>Dr. Farooq Latif, UAE</b>
16:05 - 16:30	<b>Coffee Break</b>

### SESSION 4: HEAD & NECK CANCERS

Moderators: Dr. Abdul Rahman Sumaida, UAE | Dr. Shayan Ansari, UAE | Dr. Rana Mahmood, UAE  
Dr. Muhammad Nasim, UAE

16:30 - 16:40	NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected H&N SCC at high risk of relapse. <b>Dr. Mohamed Rizwanullah, KSA</b>
16:40 - 16:50	PD-1 blockade with toripalimab incorporated into induction chemotherapy and RT with or without concurrent cisplatin in locoregionally advanced NPC: DIAMOND phase 3 trial <b>Dr. Cherian Thampy, UAE</b>
16:50 - 17:00	Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable LA HNSCC: Phase 3 KEYNOTE-689 study <b>Dr. Hatoon Bakhribah, KSA</b>
17:00 - 17:30	Panel discussion and Q&A Discussant and Moderator: <b>Dr. Muhammad Nasim, UAE</b> Panel: <b>All Speakers</b>
17:30	<b>End of Day 1 - Main Program</b>

*\*Subject to changes*

**21-22 JUNE 2025**

DUSIT THANI ABU DHABI, UAE

## CONFERENCE PROGRAM

**DAY 2**



**22 June 2025** (Sunday)



**09:00 - 17:10**

08:55 - 09:00

Introduction

### SESSION 5: UPPER GASTROINTESTINAL CANCERS

Moderators: Dr. Hassan Ghazal, UAE | Dr. Salman Ahmed, UAE | Dr. Mahdi Al-Taher, UAE

09:00 - 09:10

Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): CheckMate 577 trial  
**Dr. Dalia Elshorbagy, UAE**

09:10 - 09:20

MATTERHORN trial: A randomized, phase 3 study of durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer (GC/GEJC)  
**Dr. Almurtaadha Mula, UAE**

09:20 - 09:30

Trastuzumab deruxtecan vs ramucirumab + paclitaxel in 2nd treatment of HER2+ unresectable/metastatic gastric cancer or GEJ adenocarcinoma: Phase 3 DESTINY-Gastric04 study  
**Dr. Tala Achkar, UAE**

09:30 - 09:40

Lenvatinib plus pembro and chemo versus chemo in advanced, metastatic gastroesophageal adenocarcinoma: Phase 3 LEAP-015 study  
**Dr. Ramanujam Singarachari, UAE**

09:40 - 09:50

PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma  
**Dr. Husam Marashi, UAE**

09:50 - 10:00

Neoadjuvant chemo with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: phase III AIO/CALGP/ACO-GAIN-Trial.  
**Dr. Abdul Rahman El Kinge, UAE**

10:00 - 10:20

Panel discussion and Q&A  
Discussant and Moderator: **Dr. Hassan Ghazal, UAE**  
Panel: **All Speakers**

10:20 - 10:40

**Coffee Break**

### SESSION 6: LOWER GASTROINTESTINAL CANCERS

Moderators: Dr. Syed Mansoor Hasnain, UAE | Dr. Abdulaziz Alhamad, KSA | Dr. Diaeddine Trad, UAE  
Dr. Aswatha Ramesh, UAE

\*Subject to changes

10:40 - 11:00	Progress in Management of Hepatocellular Carcinoma - <b>Supported by BMS</b> <b>Dr. Emad Dawoud, UAE</b>
11:00 - 11:10	Randomized trial of standard chemo alone or combined with atezolizumab as adjuvant therapy for patients with stage III dMMR colon cancer (Alliance A021502; ATOMIC). <b>Dr. Fathi Azribi, UAE</b>
11:10 - 11:20	Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6) <b>Dr. Sonia Otsmane, UAE</b>
11:20 - 11:30	First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer: BREAKWATER trial <b>Dr. Abdurahman Ahmad Alloghbi, KSA</b>
11:30 - 11:40	NIVO plus IPI vs chemo or NIVO monotherapy for MSI-H/dMMR metastatic colorectal cancer: CheckMate 8HW results <b>Dr. Dina Hamza, UAE</b>
11:40 - 11:50	Anlotinib versus bevacizumab added to standard first-line chemo for RAS/BRAF wild-type, unresectable metastatic colorectal cancer: phase 3 ANCHOR trial <b>Dr. Syed Monawer Karim, UAE</b>
11:50 - 12:10	Panel discussion and Q&A Discussant and Moderator: <b>Dr. Diaeddine Trad, UAE</b> Panel: <b>All Speakers</b>
12:10 - 12:25	IO-based combinations in 1L advanced HCC : setting long term survival as new treatment goal in advanced setting - <b>Supported by AstraZeneca</b> <b>Dr. Aref Chehal, UAE</b>
12:25 - 13:55	<b>Lunch Break</b>
<b>SESSION 7: LUNG CANCER</b> Moderators: Dr. Mariam Almarashda, UAE   Dr. Omran El Koha, UAE   Dr. Dina Hamza, UAE	
13:55 - 14:05	Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA. <b>Dr. Hassan Ghazal, UAE</b>
14:05 - 14:15	Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816. <b>Dr. Aref Chehal, UAE</b>
14:15 - 14:25	Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab <b>Dr. Emad Dawoud, UAE</b>
14:25 - 14:35	Savolitinib combined with osimertinib versus chemo in EGFR-m and MET-amplification advanced NSCLC after PD on EGFR TKI: phase 3 SACHI study. <b>Prof. Wael El-Sheshtawy, Egypt</b>
14:35 - 14:45	Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. <b>Dr. Hassan Shahryar, UAE</b>
14:45 - 14:55	Lurbinectedin (lurbi) + atezo as 1L maintenance treatment in pts with extensive-stage ESCLC: Primary results of the phase 3 IMforte trial. <b>Dr. Diaeddine Trad, UAE</b>
14:55 - 15:05	Tarlatamab versus standard of care (SOC) chemotherapy as second-line (2L) treatment for SCLC: phase 3 DeLLphi-304 trial. <b>Dr. Mudhasir Ahmad, UAE</b>

*\*Subject to changes*

15:05 - 15:20	Panel discussion and Q&A Discussant and Moderator: <b>Dr. Emad Dawoud, UAE</b> Panel: <b>All Speakers</b>
15:20 - 15:40	<b>Coffee Break</b>
<b>SESSION 8: GYNAE / RARE CANCERS</b> Moderators: Dr. Khalifa Alkaabi, UAE   Dr. Mohsin Malik, UAE   Dr. Hassan Ghazal, UAE Dr. Khalid Balaraj, UAE	
15:40 - 15:50	TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7) <b>Dr. Thikra Hassan, UAE</b>
15:50 - 16:00	FIRST/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC). <b>Dr. Muhammad Nasim, UAE</b>
16:00 - 16:10	ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72) <b>Dr. Faisal Azam, KSA</b>
16:10 - 16:20	Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. <b>Dr. Hassan Jaafar, UAE</b>
16:20 - 16:30	Dual Targeting for Optimizing advanced Endometrial Cancer Outcomes - Supported by <b>AstraZeneca</b> <b>Dr. Emad Dawoud, UAE</b>
16:30 - 16:40	Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial. <b>Dr. Mohammad Hourani, UAE</b>
16:40 - 16:50	Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC). <b>Dr. Mawada Hussein, UAE</b>
16:50 - 17:10	Panel discussion and Q&As Discussant and Moderator: <b>Dr. Hassan Ghazal, UAE</b> Panel: <b>All Speakers</b>
17:10	<b>End of Conference</b>

*\*Subject to changes*